| T-cell and Retrovirus Studies | Lifetime | 5 | FR 1 | 99.79 |
| Mast cells and histamine | Lifetime | 19 | FR 1 | 99.48 |
| Lymphoma Diagnosis and Treatment | Lifetime | 86 | FR 9 | 99.70 |
| Viral-associated cancers and disorders | Lifetime | 46 | FR 5 | 99.53 |
| Vector-Borne Animal Diseases | Lifetime | 46 | FR 4 | 99.42 |
| Chronic Lymphocytic Leukemia Research | Lifetime | 174 | FR 10 | 99.47 |
| Animal Disease Management and Epidemiology | Lifetime | 152 | FR 2 | 98.94 |
| Erythrocyte Function and Pathophysiology | Lifetime | 202 | FR 6 | 98.39 |
| Hemoglobinopathies and Related Disorders | Lifetime | 223 | FR 9 | 98.37 |
| COVID-19 Clinical Research Studies | Lifetime | 621 | FR 35 | 97.75 |
| Urticaria and Related Conditions | Lifetime | 207 | FR 12 | 98.05 |
| Eosinophilic Disorders and Syndromes | Lifetime | 365 | FR 27 | 97.29 |
| Immunodeficiency and Autoimmune Disorders | Lifetime | 684 | FR 50 | 97.35 |
| Long-Term Effects of COVID-19 | Lifetime | 848 | FR 43 | 94.71 |
| Retinoids in leukemia and cellular processes | Lifetime | 809 | FR 47 | 94.32 |
| CNS Lymphoma Diagnosis and Treatment | Lifetime | 459 | FR 46 | 94.84 |
| Erythropoietin and Anemia Treatment | Lifetime | 620 | FR 23 | 91.89 |
| Histiocytic Disorders and Treatments | Lifetime | 382 | FR 32 | 91.71 |
| T-cell and Retrovirus Studies | 2021-2025 | 3 | FR 1 | 98.99 |
| Mast cells and histamine | 2021-2025 | 18 | FR 1 | 97.97 |
| Lymphoma Diagnosis and Treatment | 2021-2025 | 163 | FR 8 | 98.29 |
| COVID-19 Clinical Research Studies | 2021-2025 | 610 | FR 29 | 97.32 |
| Hemoglobinopathies and Related Disorders | 2021-2025 | 115 | FR 10 | 96.42 |
| Viral-associated cancers and disorders | 2021-2025 | 110 | FR 5 | 95.22 |
| Erythrocyte Function and Pathophysiology | 2021-2025 | 87 | FR 5 | 92.96 |
| Blood groups and transfusion | 2021-2025 | 196 | FR 22 | 91.50 |
| Chronic Lymphocytic Leukemia Research | 2021-2025 | 911 | FR 56 | 91.39 |
| Eosinophilic Disorders and Syndromes | 2021-2025 | 249 | FR 12 | 89.86 |
| Immunodeficiency and Autoimmune Disorders | 2021-2025 | 575 | FR 43 | 87.85 |
| Vector-Borne Animal Diseases | 2021-2025 | 497 | FR 17 | 85.60 |
| Iron Metabolism and Disorders | 2021-2025 | 611 | FR 19 | 84.69 |
| Animal Disease Management and Epidemiology | 2021-2025 | 801 | FR 24 | 85.08 |
| Urticaria and Related Conditions | 2021-2025 | 575 | FR 25 | 82.27 |
| Vascular Tumors and Angiosarcomas | 2021-2025 | 614 | FR 61 | 63.03 |
| Veterinary Oncology Research | 2021-2025 | 830 | FR 11 | 65.19 |
| Otitis Media and Relapsing Polychondritis | 2021-2025 | 537 | FR 108 | 63.45 |
